stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) EPS (diluted)
AMNEAL PHARMACEUTICALS, INC.'s EPS (diluted) for fiscal 2025 was $0.22, compared with −$0.38 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.52. Over the past ten years it has ranged from −$6.53 (fiscal 2017) to $0.61 (fiscal 2020); the current reading is higher than 80% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. AMNEAL PHARMACEUTICALS, INC. ranks 18th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.22 | — |
| FY2024 | −$0.38 | — |
| FY2023 | −$0.48 | — |
| FY2022 | −$0.86 | — |
| FY2021 | $0.07 | (88.52%) |
| FY2020 | $0.61 | — |
| FY2019 | −$2.74 | — |
| FY2018 | −$0.16 | — |
| FY2017 | −$6.53 | — |
| FY2015 | $0.54 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.04 | (79.61%) |
| Jun 2026 | $0.18 | (5.26%) |
| Mar 2026 | $0.19 | 72.73% |
| Dec 2025 | $0.11 | 1,000.00% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| SUPN Indivior Pharmaceuticals Inc. compare | $3.58 |
| LQDA Liquidia Corporation compare | $1.37 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $0.52 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AMRX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement